Animal models of schizophrenia

Neuroscience Research Communications

Volumn 26, Issue 3, 2000, Pages 279-288

  De Hert, M ^a   Ellenbroek, B ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Aetiology; Animal models; Maternal deprivation; Neurodevelopment; Review; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; HUMAN; LATENT INHIBITION; NONHUMAN; PREPULSE INHIBITION; REVIEW; SCHIZOPHRENIA; SENSORY NERVE;

EID: 0033933621     PISSN: 08936609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6769(200005/06)26:3<279::AID-NRC14>3.0.CO;2-J     Document Type: Review

References (43)

1. Andreasen NC. Schizophrenia, From Mind to Molecule. WashingtonDC: American Psychiatric Press, 1994.
2. De Hert M, Peuskens J. Schizofrene psychose. In: De Hert M, Thys E, Peuskens J, Petry D, Van Raay B editors. Zin in waanzin, de wereld van schizofrenie. Antwerpen: EPO; 1996. p 9-32.
3. De Hert M. Peuskens J. Schizofrene psychose/La psychose schizophrénique. Medi-sfeer 1998;79: 18-25.
4. De Hert M, Peuskens J. Schizofrenie psychosis. In: De Hert M, Bussels J, Lindström E, Abrahams F, Fransens C, Peuskens J. Psychosis evaluation tool for common use by caregivers. Antwerpen: EPO; 1999. p 8-39.
5. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine, Br J Psychiatry 1980;137: 383-386.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Psychiatric Disorders, fourth edition. Washington: American Psychiatric Association Press; 1994. p 173-316.
7. Westermeyer JF, Harrow M. Course and outcome in schizophrenia. In: Tsuang MT, Simpson JC editors, Handbook of schizophrenia, Vol 3, Amsterdam: Elsevier Science Publisher; 1988. p 205-244.
8. De Hert M, Thys E, Boydens J, Gilis P, Kesteloot K, Verhaegen L, Peuskens J. Health care expenditure on schizophrenic patients in Belgium. Schizophr Bull 1998; 24: 519-527.
9. Wyatt R. Neuroleptics and natural course of schizophrenia. Schizophr Bull 1991;17:325-351.
10. Peuskens J, De Hert M. Good medical practice antipsychotics. Copenhagen, Lundbeck, 1997.
11. Nuechterlein KH, Dawson M. A heuristic vulnerability/stress model of schizophrenia. Schizophr Bull 1984;10:300-312.
12. Nasrallah HA. Neurodevelopmental pathogenesis of schizophrenia. Psych Clin N Am 1993;16: 269-280.
13. Prescott CA, Gottesman II. Genetically mediated vulnerability to schizophrenia. Psych Clin N Am 1993;16:245-267.
14. Sharma T, Murray R. Aetiological theories in schizophrenia. Curr Op in Psych 1993;6:80-84.
15. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psych 1987;44:660-670.
16. Weinberger DR. Schizophrenia as a neurodevelopment disorder. 293-323. In: Hirsch SR, Weinberger DR. editors. Schizophrenia, Oxford: Blackwell Science 1995. p 293-323.
17. Torrey F. Surviving Schizophrenia. A family manual., New York: Harper Row Publishers, 1983.
18. Peuskens J. Proper psychosocial rehabilitation for stabilized patients with schizophrenia: the role of new therapies. Europ Neuropsychopharmacolog 1996;6:7-12.
19. De Hert M, Sperans F. In therapy. Antwerpen, EPO, 1998.
20. Ellenbroek BA, Lubbers LJ, Cools AR. Activity of "seroquel" (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 1996;15:406-416.
21. Sams Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in the rat: A possible animal model of schizophrenia. Behav Pharmacol 1996;7:3-23.
22. Ellenbroek BA, Cools AR. Animal models of psychotic disturbances. In: den Boer JA, Westenberg HGM, van Praag HM, editors. Advances in the neurobiology of schizophrenia. Chichester: John Wiley & Sons Ltd., 1995. p 89-109.
23. Ellenbroek BA, Cools AR. Animal models with construct validity for schizophrenia. Behav Pharmacol 1990;1:469-490.
24. Baruch I, Hemsley DR, Gray JA. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 1988;176:598-606.
25. Gray NS, Pilowsky LS, Gray JA, Kerwin RW. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 1995;17:95-107.
26. Swerdlow NR, Braff DL, Hartston H, Perry W, Geyer MA. Latent inhibition in schizophrenia. Schizophr Res 1996;20:91-103.
27. Williams JH, Wellman NA, Geaney DP, Cowen PJ, Feldon J, Rawlins JN. Reduced latent inhibition in people with schizophrenia: an effect of psychosis or its treatment. Br J Psychiatry 1998;172:243-249.
28. Braff D, Stone C, Callaway E, Geyer MA, Glick ID, Bali L. Prestimulus effects of human startle reflex in normals and schizophrenics. Psychophysiology 1978;15:339-343.
29. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies Arch Gen Psychiatry 1990;47:181-188.
30. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 1982;17:649-654.
31. de Bruin NMWJ, Ellenbroek BA, Cools AR, Coenen AML, van Luijtelaar ELJM. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology 1999;142:9-17.
32. Miyazato H, Skinner RD, Reese NB, Mukawa J, Garcia RE. Midlatency auditory evoked potentials and the startle response in the rat. Neuroscience 1996;75:289-300.
33. Adler LE, Rose GM, Freedman R. Neurophysiological studies of sensory gating in rats: effects of amphetamine, phencyclidine and haloperidol. Biol Psychiatry 1986;21:787-798.
34. Ellenbroek BA, van Luijtelaar ELJM, Frenken M, Cools AR. Sensory gating in rats: Lack of correlation between auditory evoked potential gating and prepulse inhibition. Schizophr Bull 1999; in press.
35. Nagamoto HT, Adler LE, Waldo MC, Griffith J, Freedman R. Gating of auditory response in schizophrenics and normal controls. Effects of recording site and stimulation interval on the P50 wave. Schizophr Res 1991;4:31-40.
36. Swerdlow NR, Benbow CH, Sisook S, Geyer MA, Braff DL. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorders. Biol Psychiatry 1993;33:298-301.
37. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1995;58:192-200.
38. Swerdlow NR. Startle in Tourette's syndrome. Biol Psychiatry 1998;44:935-936.
39. Baker NJ, Staunton M, Adler LE, Gerhardt GA, Drebing C, Waldo M, Nagamoto H, Freedman R. Sensory gating deficits in psychiatric inpatients: Relation to catecholamine metabolites in different diagnostic groups. Biol Psychiatry 1990;27:519-528.
40. Ellenbroek BA, Sams Dodd F, Cools AR. Simulation models for schizophrenia. In: Ellenbroek BA, Cools AR, editors Atypical antipsychotics. Basel: Birkhauser Verlag, 1999: (in press).
41. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 1995;122:35-43.
42. Geyer MA, Wilkinson LS, Humby T, Robbins TW. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psych 1993;34:361-372.
43. Ellenbroek BA, van den Kroonenberg PTJM, Cools AR. The effects of an early stressful life event on sensorimotor gating in adult rats. Schizophr Res 1998;30:251-260.